Drugs that contain Sumatriptan

1. List of Tosymra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268791 UPSHER SMITH LABS Alkylglycoside compositions for drug administration
May, 2026

(3 years from now)

US8440631 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(3 years from now)

US9283280 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(3 years from now)

US11337962 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9974770 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9610280 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US10603305 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9211282 UPSHER SMITH LABS Formulations comprising triptan compounds
Jul, 2031

(8 years from now)

Market Authorisation Date: 25 January, 2019

Treatment: Acute treatment of migraine

Dosage: SPRAY;NASAL

More Information on Dosage

TOSYMRA family patents

56

United States

7

European Union

5

Australia

5

Japan

4

Russia

4

Korea, Republic of

4

China

4

Canada

3

Brazil

3

Spain

3

United Kingdom

2

Denmark

2

Mexico

2

India

2

New Zealand

1

Israel

1

South Africa

IB

1

IB

1

Hong Kong

1

Morocco

1

Germany

1

Singapore

EA

1

EA

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic